Dr. Spigel on CheckMate-331 Trial for SCLC

David Spigel, MD
Published: Wednesday, Jun 29, 2016


David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the ongoing CheckMate-331 trial, which is investigating nivolumab (Opdivo) versus chemotherapy in relapsed patients with small cell lung cancer (SCLC) after first-line platinum-based chemotherapy.

The open-label, international, randomized phase III trial, which is exploring the role of nivolumab versus topotecan, is currently enrolling patients. The primary endpoint, Spigel adds, is overall survival.

Researchers are hopeful that the immunotherapy agent will show a survival benefit when compared with topotecan, as well as demonstrate a more favorable safety profile.

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the ongoing CheckMate-331 trial, which is investigating nivolumab (Opdivo) versus chemotherapy in relapsed patients with small cell lung cancer (SCLC) after first-line platinum-based chemotherapy.

The open-label, international, randomized phase III trial, which is exploring the role of nivolumab versus topotecan, is currently enrolling patients. The primary endpoint, Spigel adds, is overall survival.

Researchers are hopeful that the immunotherapy agent will show a survival benefit when compared with topotecan, as well as demonstrate a more favorable safety profile.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x